

**P&T Motion History  
Antiemetics**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<p><b>amisulpride</b> aprepitant/fosaprepitant dolasetron doxylamine/pyridoxine fosnetupitant/palonosetron granisetron netupitant/palonosetron ondansetron palonosetron rolapitant</p>	<p>After considering the evidence of safety, efficacy and special populations I move that amisulpride, aprepitant/fosaprepitant dolasetron, doxylamine/pyridoxine, fosnetupitant/palonosetron, granisetron, netupitant/palonosetron, ondansetron, palonosetron and rolapitant are efficacious for their FDA approved indications. The preferred drug list must include at least one medication that includes alternate routes approved in both adults and children. The antiemetics can be subject to therapeutic interchange within their mechanism of action in the Washington preferred drug list. The preferred drug list must include a neurokinin 1 antagonist for patients receiving highly emetogenic chemotherapy and/or radiation therapy.</p> <p>Motion: Beste 2<sup>nd</sup>: Hudson</p>	<p>June 26, 2024</p>	<p>N/A</p>	<p>No</p>	<p>Passed unanimous</p>

**BOLD** = new this review

Grey = not reviewed in this archive report, ineligible to be preferred